meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
<span style="margin-left: 0em;">endocrine therapy</span>
<span style="margin-left: 1em;">letrozole <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">phosphoinositide 3-kinase (PI3K) inhibitor</span>
<span style="margin-left: 1em;">alpelisib based treatment</span>
<span style="margin-left: 2em;">alpelisib plus letrozole <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 1em;">buparlisib based treatment</span>
<span style="margin-left: 2em;">buparlisib plus letrozole <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
objective responses (ORR) (2)
pCR (2)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
letrozole
alpelisib plus letrozole
buparlisib plus letrozole
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
letrozole
alpelisib plus letrozole
buparlisib plus letrozole
letrozole
---
NA
NA
alpelisib plus letrozole
NA
---
NA
buparlisib plus letrozole
NA
NA
---
pathologies: 351,357 - treatments: 1431
result logic
×
Study list
